Reference no: EM132461223

Question 1: Your company has issued several financial instruments in the past year and you must determine how to account for each of these under ASPE and IFRS.

Point 1: A third financial instrument was a forward contract. The company agreed to buy $5.5 million in U.S. currency for $5,775,000 (U.S. $1 = Canadian $1.05). On December 14, 2020 the new value was U.S. $ = Canadian $ 1.07.

Point 2: On September 1, 2020, your company sold at 103 (plus accrued interest) 4,000 of its $1,000 face value, 10-year, 8%, non-convertible bonds with detachable stock warrants. Each bond carried two detachable warrants; each warrant was for one common share at a specified price of $12 per share. Shortly after issuance, the warrants were selling for $6 each. Assume there is no fair value available for the bonds. Interest is payable on December 1 and June 1. Show both methods.

Point 3: The company established a stock appreciation rights program for the president. The program entitled the president to receive cash for the difference between the common shares fair value and the pre-established price of $20 which was the fair value on January 1, 2020 on 20,000 SARs. The date of the grant was January 1, 2020 and the required employment (service period) is two years. Assume the common shares' fair value fluctuated as follows: December 31, 2020, $24; December 31, 2021, $23 and December 31, 2022, $26. Assume, also, that the president exercised half of the SARs on January 1, 2023.

Point 4: The last item that you need to consider is a contract that your company signed on November 15, 2020 agreeing to purchase 100 barrels of oil at $99 per barrel. Your company anticipated that the price of oil would increase significantly. Since the company requires oil in the production of its product and will need to take delivery of the oil in the new year, they wanted to reduce the risk of increased costs for the oil.